JP2006507839A5 - - Google Patents

Download PDF

Info

Publication number
JP2006507839A5
JP2006507839A5 JP2004557456A JP2004557456A JP2006507839A5 JP 2006507839 A5 JP2006507839 A5 JP 2006507839A5 JP 2004557456 A JP2004557456 A JP 2004557456A JP 2004557456 A JP2004557456 A JP 2004557456A JP 2006507839 A5 JP2006507839 A5 JP 2006507839A5
Authority
JP
Japan
Prior art keywords
antibody
hinge region
composition
exogenous
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2004557456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006507839A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/038198 external-priority patent/WO2004050847A2/en
Publication of JP2006507839A publication Critical patent/JP2006507839A/ja
Publication of JP2006507839A5 publication Critical patent/JP2006507839A5/ja
Abandoned legal-status Critical Current

Links

JP2004557456A 2002-11-27 2003-11-26 乳中に安定して産生される改変抗体およびその製造方法 Abandoned JP2006507839A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42960602P 2002-11-27 2002-11-27
PCT/US2003/038198 WO2004050847A2 (en) 2002-11-27 2003-11-26 Modified antibodies stably produced in milk and methods of producing same

Publications (2)

Publication Number Publication Date
JP2006507839A JP2006507839A (ja) 2006-03-09
JP2006507839A5 true JP2006507839A5 (cg-RX-API-DMAC10.html) 2007-04-05

Family

ID=32469344

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004557456A Abandoned JP2006507839A (ja) 2002-11-27 2003-11-26 乳中に安定して産生される改変抗体およびその製造方法

Country Status (8)

Country Link
US (1) US20050097625A1 (cg-RX-API-DMAC10.html)
EP (1) EP1565564A4 (cg-RX-API-DMAC10.html)
JP (1) JP2006507839A (cg-RX-API-DMAC10.html)
CN (1) CN1729298A (cg-RX-API-DMAC10.html)
AU (1) AU2003298787A1 (cg-RX-API-DMAC10.html)
BR (1) BR0316643A (cg-RX-API-DMAC10.html)
CA (1) CA2506629A1 (cg-RX-API-DMAC10.html)
WO (1) WO2004050847A2 (cg-RX-API-DMAC10.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3751873T2 (de) 1986-04-09 1997-02-13 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US7700097B2 (en) * 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
ES2642787T3 (es) * 2005-10-21 2017-11-20 Lfb Usa, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
AU2012201010B2 (en) * 2005-10-21 2015-01-22 Genzyme Corporation Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
EP2061811A2 (en) * 2006-09-01 2009-05-27 ZymoGenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
PL2238166T3 (pl) 2007-10-05 2014-07-31 Genentech Inc Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu
US20110229460A1 (en) * 2008-05-01 2011-09-22 Gtc Biotherapeutics, Inc. anti-cd137 antibody as an agent in the treatment of inflammatory conditions
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
AU2011350895B2 (en) 2010-12-30 2015-05-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Glycols as pathogen inactivating agents
EP2741769B1 (en) * 2011-08-10 2019-01-02 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated antibodies
EP2956003A2 (en) 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Proteins with modified glycosylation and methods of production thereof
MX2015010429A (es) * 2013-02-13 2016-05-16 Lab Francais Du Fractionnement Cetuximab con glicosilación modificada y sus usos.
KR20160002713A (ko) * 2013-02-13 2016-01-08 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 고도로 갈락토실화된 항-tnf-알파 항체 및 이의 용도
CA2916566A1 (fr) 2013-07-05 2015-01-08 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Matrice de chromatographie d'affinite
FR3025515B1 (fr) 2014-09-05 2016-09-09 Lab Francais Du Fractionnement Procede de purification d'un anticorps monoclonal
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
FR3034420A1 (fr) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303
FR3034419B1 (fr) 2015-04-02 2017-12-15 Lab Francais Du Fractionnement Procede de purification d'une proteine recombinante therapeutique a partir d'un lait transgenique
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
JP7122974B2 (ja) 2016-05-11 2022-08-22 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 変異免疫グロブリン結合ポリペプチド
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
EP3455241B1 (en) 2016-05-11 2022-02-23 Cytiva BioProcess R&D AB Method of cleaning and/or sanitizing a separation matrix
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
WO2017194592A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of storing a separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
FR3060394B1 (fr) 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-amhrii
FR3060395B1 (fr) 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-her2
FR3076294B1 (fr) 2017-12-29 2022-01-28 Lab Francais Du Fractionnement Procede de purification d'anticorps a partir de lait brut
CA3223956A1 (en) 2021-12-20 2023-06-29 Vetoquinol Sa Anti-canine interleukine-31-receptor a (il-31ra) antibodies and the uses thereof
WO2024165823A2 (fr) 2023-02-09 2024-08-15 Commissariat A L'energie Atomique Et Aux Energies Alternatives Fragment fab mutant pour l'obtention de conjugués mono- ou bi-fonctionnalisés site-spécifiques
WO2025114614A1 (en) 2023-11-30 2025-06-05 Vetoquinol Sa Anti-canine interleukine-4-receptor alpha (il-4rα) antibodies and the uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2459619B1 (fr) * 1979-06-26 1983-07-29 Agronomique Inst Nat Rech Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede
DE3432718C1 (de) * 1984-09-06 1986-05-22 Biotest Pharma GmbH, 6000 Frankfurt Verfahren zur Herstellung einer Loesung von Milch- und/oder Kolostralimmunglobulinen
US4897465A (en) * 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
CA2184688A1 (en) * 1994-03-09 1995-09-14 Pedro Antonio Prieto Transgenic animals producing oligosaccharides and glycoconjugates
AU707440B2 (en) * 1994-03-29 1999-07-08 Celltech Therapeutics Limited Antibodies against E-selectin
CA2205091A1 (en) * 1994-12-23 1996-07-04 Zeneca Limited Chemical compounds
US6268487B1 (en) * 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk

Similar Documents

Publication Publication Date Title
JP6473423B2 (ja) 修飾された免疫グロブリン重鎖配列を有する非ヒト動物
KR102276752B1 (ko) 단일 도메인 결합 단백질을 생산하는 비-인간 동물
LTC3284753I2 (cg-RX-API-DMAC10.html)
WO2003040169A3 (en) Human monoclonal antibodies to dendritic cells
NO20040752L (no) Humane antistoffer spesifikke for interleukin 15 (IL-15)
WO2004076620A3 (en) Human antibodies specific for interleukin 15 (il-15)
DK1210374T3 (da) Humane, monoklonale antistoffer over for prostataspecifikt membranantigen
ATE527278T1 (de) Humane monoklonale antikörper gegen interleukin 8 (il-8)
WO2003064606A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
JP2009525758A5 (cg-RX-API-DMAC10.html)
ATE553131T1 (de) Humane monoklonale antikörper gegen dendritische zellen
WO2004056847A3 (en) Human monoclonal antibodies to epidermal growth factor receptor (egfr)
PL392809A1 (pl) Przeciwciało monoklonalne przeciwko CD40 i jego część wiążąca antygen, zawierająca go kompozycja i jego zastosowanie, oraz linia komórkowa, cząsteczka kwasu nukleinowego, wektor komórka gospodarza i sposób wytwarzania
RU2017106292A (ru) Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
JP2010527622A5 (cg-RX-API-DMAC10.html)
AU2003298787A1 (en) Modified antibodies stably produced in milk and methods of producing same
KR20160131118A (ko) 상이한 결합 특징을 전시하는 vl 항원 결합 단백질
DE102009047243A1 (de) Monospezifische Polypeptidreagenzien
WO2008048871A3 (en) Cynomolgus il-13 mutein proteins, antibodies, compositions, methods and uses